Obesity is a severe healthcare care issue throughout the globe. Cercato and Fonseca (2019, p. 1) mention that more than 650 million people suffer from this problem. Even though this condition is harmful on its own, it also contributes to additional health problems. In particular, obesity is challenging because it leads to related inflammatory diseases of the cardiovascular system. According to Cercato and Fonseca (2019, p. 1), hormones and peptides are responsible for the connection between obesity and cardiovascular complications. Simultaneously, inflammatory cytokines, “whose production is increased in obesity, also play an important role in the development of heart failure” (Csige et al., 2018, p. 3). Chehimi, Vidal, and Elfaafari (2017, p. 1) also admit the connection between obesity and inflammatory processes because increased inflammatory adipokine secretion and adipose tissues induce adipocyte insulin resistance. It is a typical case that such conditions require medication treatments. Thus, the given dissertation proposal offers a systematic review to determine whether ghrelin, a hormone peptide, can reduce the incidence of obesity and related inflammatory diseases in cardiovascular patients.
An appropriate methodology is necessary to undertake the proposed study. The dissertation intends to locate timely and credible scholarly articles. Studies will be included if they have made an experiment to assess how treatment with ghrelin, following the use of ELISA, affect mature fat cells. The results from the selected studies will be extracted, while a recent SPSS package will help analyze and measure the data to assess the effectiveness of the method under consideration.
In conclusion, the given dissertation proposal focuses on a significant issue in the healthcare industry. This research process offers to find and analyze the existing evidence about how effective ghrelin therapy is in relation to obesity and related inflammatory diseases in cardiovascular patients. The dissertation findings will be significant because they will reveal whether there is a scientific rationale behind relying on ghrelin therapy when providing care to patients with the selected conditions.
Cercato, C. and Fonseca, F. A. (2019) ‘Cardiovascular risk and obesity’, Diabetology & Metabolic Syndrome, 11(1), pp. 1-15.
Chehimi, M., Vidal, H. and Eljaafari, A. (2017) ‘Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases’, Journal of Clinical Medicine, 6(7), pp. 1-19.
Csige, I. et al. (2018) ‘The impact of obesity on the cardiovascular system’, Journal of Diabetes Research, 2018, pp. 1-12.